KR102247944B1 - Antioxidant and whitening composition - Google Patents
Antioxidant and whitening composition Download PDFInfo
- Publication number
- KR102247944B1 KR102247944B1 KR1020190056913A KR20190056913A KR102247944B1 KR 102247944 B1 KR102247944 B1 KR 102247944B1 KR 1020190056913 A KR1020190056913 A KR 1020190056913A KR 20190056913 A KR20190056913 A KR 20190056913A KR 102247944 B1 KR102247944 B1 KR 102247944B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- glutathione
- antioxidant
- plum
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 41
- 230000002087 whitening effect Effects 0.000 title claims abstract description 39
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 32
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 97
- 108010024636 Glutathione Proteins 0.000 claims abstract description 48
- 229960003180 glutathione Drugs 0.000 claims abstract description 48
- 235000003969 glutathione Nutrition 0.000 claims abstract description 48
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 36
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 31
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 24
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 13
- 239000011707 mineral Substances 0.000 claims abstract description 13
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000005715 Fructose Substances 0.000 claims abstract description 12
- 229930091371 Fructose Natural products 0.000 claims abstract description 12
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 12
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 12
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 12
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000011718 vitamin C Substances 0.000 claims abstract description 12
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 12
- 239000000811 xylitol Substances 0.000 claims abstract description 12
- 235000010447 xylitol Nutrition 0.000 claims abstract description 12
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 12
- 229960002675 xylitol Drugs 0.000 claims abstract description 12
- 238000005469 granulation Methods 0.000 claims description 22
- 230000003179 granulation Effects 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 19
- 230000008569 process Effects 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 5
- 238000005054 agglomeration Methods 0.000 claims description 4
- 230000002776 aggregation Effects 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 29
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 6
- 239000001301 oxygen Substances 0.000 abstract description 6
- 229910052760 oxygen Inorganic materials 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 36
- 102000003425 Tyrosinase Human genes 0.000 description 28
- 108060008724 Tyrosinase Proteins 0.000 description 28
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 26
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 20
- 230000008099 melanin synthesis Effects 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 9
- 235000010755 mineral Nutrition 0.000 description 9
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 5
- 238000010609 cell counting kit-8 assay Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 4
- 208000012641 Pigmentation disease Diseases 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 229960004502 levodopa Drugs 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 3
- 101710200814 Melanotropin alpha Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007844 bleaching agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- KMVWNDHKTPHDMT-UHFFFAOYSA-N 2,4,6-tripyridin-2-yl-1,3,5-triazine Chemical compound N1=CC=CC=C1C1=NC(C=2N=CC=CC=2)=NC(C=2N=CC=CC=2)=N1 KMVWNDHKTPHDMT-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- -1 derivatives thereof Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 2
- 108010051081 dopachrome isomerase Proteins 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003061 melanogenesis Effects 0.000 description 2
- 210000002780 melanosome Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 235000021018 plums Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 description 1
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- JDSQBDGCMUXRBM-UHFFFAOYSA-N 2-[2-(2-butoxypropoxy)propoxy]propan-1-ol Chemical compound CCCCOC(C)COC(C)COC(C)CO JDSQBDGCMUXRBM-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 244000018795 Prunus mume Species 0.000 description 1
- 235000011158 Prunus mume Nutrition 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 229940117960 vanillin Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/30—Other Organic compounds
- A23V2250/31—Glutathione
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/606—Fructose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/64—Sugar alcohols
- A23V2250/6422—Xylitol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/708—Vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Nutrition Science (AREA)
- Birds (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
기존의 피부 미백 조성물은 피부에 바르는 물질이 대부분이다. 그러나 피부에 바르는 미백 조성물은 사용 시기가 한정되어 있고, 효과도 불분명하였다. 이러한 문제를 해결하기 위하여, 본 발명의 항산화 및 미백 조성물은 매실 5 중량%, 자일리톨 50 중량%, 결정과당 29.5 중량%, 비타민 C 7%, 미네랄 3 중량%, 50 중량%의 글루타치온을 함유하는 글루타치온 효모 0.5 중량% 인 것을 특징으로 하는 항산화 및 미백 조성물을 제공한다.
상기와 같은 구성에 의하여 매실의 항산화 기능과 글루타치온 효모의 활성산소 제거 기능을 이용한 식품조성물을 제공함으로서 건강한 생활을 할 수 있는 조성물을 제공한다. Most of the existing skin whitening compositions are substances applied to the skin. However, the time of use of the whitening composition applied to the skin was limited, and the effect was unclear. In order to solve this problem, the antioxidant and whitening composition of the present invention is glutathione containing 5% by weight of plum, 50% by weight of xylitol, 29.5% by weight of crystalline fructose, 7% of vitamin C, 3% by weight of minerals, and 50% by weight of glutathione. It provides an antioxidant and whitening composition, characterized in that 0.5% by weight of yeast.
By providing a food composition using the antioxidant function of plum and the active oxygen removal function of glutathione yeast by the above configuration, a composition capable of living a healthy life is provided.
Description
본 발명은 항산화 및 미백 기능이 있는 식품조성물에 관한 것으로 더욱 자세하게는 Glutathione Yeast를 함유하는 매실추출물에 관한 것이다.The present invention relates to a food composition having antioxidant and whitening functions, and more particularly, to a plum extract containing Glutathione Yeast.
본 발명 이전의 선행기술로는 홍화황 추출물을 포함하는 미백용 화장료 조성물, 미백용 식품 조성물, 상기 조성물을 포함하는 색소침착 질환의 예방 또는 완화용 건강기능성 식품, 및 색소 침착 질환의 예방 또는 치료용 약제학적 조성물에 관한 기술이 개시되어 있다.Prior art prior to the present invention includes a cosmetic composition for whitening, a food composition for whitening, a health functional food for the prevention or alleviation of pigmentation diseases containing the composition, and for the prevention or treatment of pigmentation diseases Description of the pharmaceutical composition is disclosed.
또 다른 선행기술로는 노근, 함초 및 매실 추출물을 함유하는 항산화 및 미백 화장료 조성물에 관한 것으로서, 노근의 에탄올 추출 동결 건조물에 대한 에틸아세테이트 추출 분획물과, 함초의 에탄올 추출 동결 건조물에 대한 에틸아세테이트 또는 부탄올 추출 분획물과, 매실의 에탄올 추출 동결 건조물의 혼합물을 포함하는 구성이 개시되어 있다.Another prior art relates to an antioxidant and whitening cosmetic composition containing extracts of nogeun, green tea and plum, and an ethyl acetate-extracted fraction for the ethanol-extracted freeze-dried product of Nogeun, and ethyl acetate or butanol for the freeze-dried product of ethanol-extracted green tea A composition comprising a mixture of an extracted fraction and a freeze-dried product of ethanol extraction of plum is disclosed.
기존의 피부 미백 조성물은 피부에 바르는 물질이 대부분이다. 그러나 피부에 바르는 미백 조성물은 사용시기가 한정되어 있고, 효과도 불분명하였다. 이러한 문제를 해결하기 위하여, 본 발명은 먹는 항산화 및 미백 조성물을 제공하고자한다. 또한, 본 발명은 매실의 항산화 기능과 글루타치온 효모의 활성산소 제거기능을 이용한 식품조성물을 제공한다. Most of the existing skin whitening compositions are substances applied to the skin. However, the time of use of the whitening composition applied to the skin was limited, and the effect was unclear. In order to solve this problem, the present invention is to provide an antioxidant and whitening composition for eating. In addition, the present invention provides a food composition using the antioxidant function of plum and the active oxygen removal function of glutathione yeast.
본 발명은 기존의 문제를 해결하기 위하여 하기의 과제 해결 수단을 제공한다.The present invention provides a means for solving the following problems in order to solve the existing problems.
본 발명의 항산화 및 미백 조성물은 매실 5 중량%, 자일리톨 50 중량%, 결정과당 29.5 중량%, 비타민 C 7%, 미네랄 3 중량%, 50 중량%의 글루타치온을 함유하는 글루타치온 효모 0.5 중량% 인 것을 특징으로 하는 항산화 및 미백 조성물을 제공한다.The antioxidant and whitening composition of the present invention is 0.5% by weight of glutathione yeast containing 5% by weight of plum, 50% by weight of xylitol, 29.5% by weight of crystalline fructose, 7% of vitamin C, 3% by weight of minerals, and 0.5% by weight of glutathione. It provides an antioxidant and whitening composition.
또 다른 실시예로, 본 발명의 항산화 및 미백 조성물은 매실 5 중량%, 자일리톨 50 중량%, 결정과당 29 중량%, 비타민 C 7%, 미네랄 3 중량%, 50 중량%의 글루타치온을 함유하는 글루타치온 효모 1 중량% 인 것을 특징으로 하는 항산화 및 미백 조성물을 제공한다.In another embodiment, the antioxidant and whitening composition of the present invention is a glutathione yeast containing 5% by weight of plum, 50% by weight of xylitol, 29% by weight of fructose, 7% of vitamin C, 3% by weight of minerals, and 50% by weight of glutathione. It provides an antioxidant and whitening composition, characterized in that 1% by weight.
또 다른 실시예로, 본 발명의 항산화 및 미백 조성물은 매실 5 중량%, 자일리톨 50 중량%, 결정과당 28.5 중량%, 비타민 C 7%, 미네랄 3 중량%, 50 중량%의 글루타치온을 함유하는 글루타치온 효모 1.5 중량% 인 것을 특징으로 하는 항산화 및 미백 조성물을 제공한다.In another embodiment, the antioxidant and whitening composition of the present invention is a glutathione yeast containing 5% by weight of plum, 50% by weight of xylitol, 28.5% by weight of crystalline fructose, 7% of vitamin C, 3% by weight of minerals, and 50% by weight of glutathione. It provides an antioxidant and whitening composition, characterized in that 1.5% by weight.
본 발명은 상기와 같은 구성에 의하여 항산화 실험 결과 Fe chelating 능력을 측정한 결과 Glutathione 효모를 함유한 실험군에서 유의한 저해 효과를 나타내었다. 또한 본 발명의 멜라닌 생합성의 경우에도 X50배를 희석한 Glutathione 효모를 함유한 실험군에서 통계적으로 유의하게 더욱 생합성을 저해하는 효과를 나타내었다. 또한 글루타치온 효모를 이취 없이 섭취하기 위하여 HPMC를 첨가하여 과립화하는 과정에서 항산화 활성과 미백효과는 영향을 받지 않았다.The present invention is a result of the antioxidant experiment by the configuration as described above Fe As a result of measuring the chelating ability, a significant inhibitory effect was shown in the experimental group containing Glutathione yeast. In addition, in the case of the melanin biosynthesis of the present invention, the experimental group containing the X50-fold diluted Glutathione yeast showed a statistically significant effect of further inhibiting biosynthesis. In addition, the antioxidant activity and whitening effect were not affected in the process of granulating by adding HPMC in order to consume glutathione yeast without off-flavor.
또한, 본 발명은 매실의 항산화 기능과 글루타치온 효모의 활성산소 제거 기능을 이용한 식품조성물을 제공함으로서 건강한 생활을 할 수 있는 조성물을 제공한다. In addition, the present invention provides a composition capable of living a healthy life by providing a food composition using the antioxidant function of plum and the function of removing active oxygen from glutathione yeast.
도1은 Fe chelating ability
도 2는 Tyrosinase inhibition rate
도3은 Cytotoxicity of extract on B16F0 cells
도4는 세포 내 tyrosinase 활성 저해 효과
도5는 멜라닌 생합성 저해 효과
도6은 항산화 활성 측정
도7은 The ABTS+ cation radical scavenging activity of containing HPMC products and except HPMC product
도8은 Frap The Fe3+-TPTZ-Fe2+-TPTZ reducing ability of containing HPMC products and except HPMC product
도9는 The Fe2+ chelating of different of containing HPMC products and except HPMC product and except HPMC product
도10은 Tyrosinase(from mushroom) inhibition rate of containing HPMC products and except HPMC productFigure 1 is Fe chelating ability
Figure 2 is the Tyrosinase inhibition rate
Figure 3 is a Cytotoxicity of extract on B16F0 cells
Figure 4 shows the effect of inhibiting tyrosinase activity in cells
5 is a melanin biosynthesis inhibitory effect
Figure 6 is an antioxidant activity measurement
7 shows The ABTS+ cation radical scavenging activity of containing HPMC products and except HPMC product.
Figure 8 shows Frap The Fe3+-TPTZ-Fe2+-TPTZ reducing ability of containing HPMC products and except HPMC product.
9 shows The Fe2+ chelating of different of containing HPMC products and except HPMC product and except HPMC product.
Figure 10 is Tyrosinase (from mushroom) inhibition rate of containing HPMC products and except HPMC product
최근 생활과 소득 수준이 향상되면서 삶의 질을 향상시키기 위해 많은 관심이 높아지고 있다. 특히 노화와 각종 염증질환, 암의 대처 방안으로 항산화 물질을 비롯한 체내 질병과 대사를 위한 생리활성물질 개발에 대해 관심이 증대 되고 있다. 생체 내에 필요한 에너지 공급을 위해 생화학적 산화 반응은 끊임없이 일어나며 이 과정 중에 발생하는 유해산소라 불리는 활성산소 (reactive oxygen species, ROS) 는 가장 안정한 형태의 산소인 삼중항산소가 산화, 환원과정에서 생성되는 일중항산소인 Superoxide anion, hydroxyl radical, hydrogen peroxide과 같은 불안정한 상태의 프리라디칼(free radical) 및 과산화수소 (H2O2)로 불안정하고 산화력이 높아 생체물질과 쉽게 반응하기 때문에 인체 내에서 제거되지 못하면 산화적 스트레스 (oxidative stress)를 유발하게 되며, 이러한 산화적 스트레스 중 피부 광 손상의 중요한 인자인 O2 및 OH는 피부에 존재하는 항산화 물질의 파괴, 지질과산화반응의 개시, 단백질 및 DNA 산화, 결합조직 성분인 콜라겐(collagen)과 엘라스틴(elastin) 및 히알루 론산(hyaluronic acid) 등의 결합사슬 절단 및 비정상적인 교차결합에 의한 주름생성, 멜라닌 생성촉진 등 피부의 노화를 가속화 한다.Recently, as the level of living and income has improved, a lot of interest is increasing to improve the quality of life. In particular, interest in the development of physiologically active substances for metabolism and diseases in the body, including antioxidants, is increasing as a countermeasure against aging, various inflammatory diseases, and cancer. Biochemical oxidation reactions constantly occur in order to supply energy necessary for the living body, and reactive oxygen species (ROS), which is called harmful oxygen, generated during this process is the most stable form of oxygen, triplet oxygen, which is produced during the oxidation and reduction process. It is unstable with unstable free radicals and hydrogen peroxide (H2O2) such as singlet oxygen superoxide anion, hydroxyl radical, and hydrogen peroxide. (oxidative stress), and among these oxidative stresses, O 2 and OH, which are important factors of skin light damage, destroy antioxidants present in the skin, initiate lipid peroxidation, oxidation of proteins and DNA, and connective tissue components. It accelerates skin aging such as cleavage of binding chains such as collagen, elastin, and hyaluronic acid, wrinkle formation due to abnormal cross-linking, and promotion of melanin production.
피부는 나이가 들어감에 따라 자연스럽게 생기는 내인성노화 (Intrinisc againg)와 누적된 햇빛의 노출에 의해 유발되는 광노화 (Photoaging)가 있다. 이 중 광노화는 피부노화의 주된 원인으로 최근 급격하게 변화하는 산업화와 환경오염으로 인해 오존층이 파괴되어 자외선 조사량이 심각하게 방출됨으로써 증가하고 있는 추세이다. 자외선 (Ultravoiler. UV)은 태양에서 발생되는 400nm 이하의 파장을 가지는 광선으로 생체에 많은 변화를 가져온다. 이는 진피의 유두층, 그물층까지 영향을 미치고 탄력소와 아교질의 붕괴로 탄력감소, 조기노화, 모세혈관의 확장 및 손상으로 피부의 기저층을 와해시키며, 피부암 발생 가능성도 높아진다. 모발 역시 태양광선에 노출되면 건조해지고, 강도가 감소되며, 표면이 거칠어지고 쉽게 부서지게 된다. 이렇게 태양광선에 의한 광화학적 분해는 모발이나 피부 단백질과 멜라닌에 자극을 주어 내부세포, 세포막 혼합체, 멜라닌의 파괴가 일어나게 된다. 멜라닌은 검은 색소와 단백질의 복합체이며 사람의 머리카락과 피부색을 이루는 색소로서 양이 많으면 피부색이 황갈색에서 흑갈색을 띄고 양이 적을수록 색이 엷어지게 된다. 멜라닌의 경우 외부환경, 자외선으로부터 피부세포를 보호하는 역할을 하지만 과도한 자외선 노출이나 피부노화로 인해 과잉생성 될 경우 피부에 색소가 침착되어 기미, 주근깨를 형성하며 멜라닌 전구물질의 독성으로 피부암의 원인이 되기도 한다. 따라서 이러한 색소 침착현상을 방지하기 위해서는 멜라닌 생성과정의 일부분을 저해하여 멜라닌의 생성을 감소시켜야 한다. 멜라닌의 생합성에서 가장 중요한 단계는 타이로시네이즈 (tyrosinase) 의 촉매작용을 통하여 일어나는 초기 반응으로 표피의 기저층에 존재하는 melanocyte (멜라노사이트) 내의 melanosome (멜라노좀) 이라는 소포체에서 먼저 tyrosinase, tyrosinase related protein-1(TRP-1)과 dopachrome tautomerase (DCT)등의 효소에 의해 생성된다.The skin has intrinsc againg, which occurs naturally with age, and photoaging, which is caused by accumulated sunlight exposure. Among them, photoaging is a major cause of skin aging, and it is increasing as the ozone layer is destroyed due to industrialization and environmental pollution, which are rapidly changing in recent years, and the amount of ultraviolet irradiation is seriously released. Ultraviolet (Ultravoiler. UV) is a ray of light with a wavelength of 400 nm or less generated from the sun and causes many changes in the living body. This affects the papillary layer and the reticulum layer of the dermis, and the base layer of the skin is damaged by loss of elasticity, premature aging, expansion and damage of capillaries due to the collapse of elasticity and collagen, and the likelihood of skin cancer is increased. Hair, too, becomes dry when exposed to sunlight, its strength decreases, and its surface becomes rough and brittle. In this way, photochemical decomposition by sunlight stimulates hair or skin proteins and melanin, resulting in destruction of internal cells, cell membrane mixtures, and melanin. Melanin is a complex of black pigment and protein, and it is a pigment that makes up the color of human hair and skin. When the amount is high, the skin color becomes yellowish brown to blackish brown, and the smaller the amount, the lighter color. In the case of melanin, it protects skin cells from the external environment and ultraviolet rays. However, when over-produced due to excessive exposure to ultraviolet rays or skin aging, pigmentation is deposited on the skin to form spots and freckles, and the toxicity of melanin precursors causes skin cancer. It is also possible. Therefore, in order to prevent such pigmentation phenomenon, it is necessary to reduce the production of melanin by inhibiting a part of the melanin production process. The most important step in the biosynthesis of melanin is the initial reaction that occurs through the catalytic action of tyrosinase.In the endoplasmic reticulum called melanosome (melanosome) in the base layer of the epidermis, tyrosinase, tyrosinase related protein It is produced by enzymes such as -1 (TRP-1) and dopachrome tautomerase (DCT).
앞서 언급된 타이로시네이즈(tyrosinase)는 멜라닌 생성 첫 단계를 일으키는 중요한 효소로, tyrosin (타이로신)이 3, 4-dihydroxy phenylalanine (DOPA, 도파)를 거쳐 DOPAquinone (도파퀴논)으로 전환되고, DOPAquinone 으로부터 자동 산화 반응과 효소 반응으로 DOPAchrome (도파크롬)을 거쳐 흑갈색의 공중합체인 멜라닌을 생성하게 된다. The aforementioned tyrosinase is an important enzyme that causes the first stage of melanogenesis, and tyrosin (tyrosine) is converted to DOPAquinone (dopaquinone) through 3,4-dihydroxy phenylalanine (DOPA, dopa), and from DOPAquinone. It produces melanin, a dark brown copolymer, through DOPAchrome (Dopachrome) through an automatic oxidation reaction and an enzymatic reaction.
현재 과도하게 생성된 멜라닌의 부정적인 기능 때문에 미백제의 개발에 있어서, 멜라닌 생합성 대사에 대한 연구가 진행 중이며 그 중에서도 멜라닌 생성의 주요 효소인 타이로시네이즈 (tyrosinase) 활성을 저해함으로써 멜라닌 생성을 억제시켜 미백효과를 유도할 수 있다.Currently, due to the negative function of excessively produced melanin, studies on the metabolism of melanin biosynthesis are underway in the development of whitening agents. Among them, whitening by inhibiting melanin production by inhibiting the activity of tyrosinase, a major enzyme in melanogenesis. It can induce an effect.
기존 화장품 분야에서는 미백성분으로서, tyrosinase 효소활성을 억제하는 물질로 알려진 코지산 (kojic acid), 알부틴(arbutin) 을 비롯한 하이드로퀴논 (hydroquinone), 비타민C 및 이들의 유도체와 각종 식물 추출물이 사용되어 왔다. 그러나, 이런 물질들은 불안정하여 분해나 착색, 이취, 효과의 불분명, 피부와 제형 안전성 문제뿐만 아니라 돌연변이 유발 및 세포독성문제 등으로 그 사용이 제한되고 있는 실정이다. 따라서 기존 미백제가 갖고 있는 여러 단점을 극복하고자 최근에는 피부에 안전한 천연물을 이용한 미백제 개발에 많은 연구가 진행되고 있다.In the existing cosmetics field, as whitening ingredients, hydroquinones, including kojic acid and arbutin, which are known to inhibit tyrosinase enzyme activity, vitamin C, derivatives thereof, and various plant extracts have been used. . However, these substances are unstable, and their use is limited due to decomposition, coloration, off-flavor, unclear effect, safety problems of skin and formulation, as well as mutagenesis and cytotoxicity problems. Therefore, in order to overcome the various disadvantages of existing whitening agents, many studies are being conducted on the development of whitening agents using natural products that are safe for the skin.
매실나무(Prunus mume)는 장미과에 속하며 원산지는 중국의 동남부지방이며 한국, 중국 및 일본의 온난한 지역에 분포하는 동양 고유종의 과수 이다. 또한 나관중의 ‘삼국지연의’에 나올 정도로 옛날부터 식용 또는 약용으로 사용되어 왔고 각종 한의서에 매실은 만성기침, 위염, 만성사, 혈뇨, 구토, 치질등 치료한 기록이 전해진다. 매실은 malic acid, citric acid, oxalic acid, succinic acid, fumaric acid 와 같은 유기산과 무기질을 많이 포함하고 있어 식욕촉진 및 위액분비를 증가하여 소화 활동과 피로회복을 도와주는 효과가 있다고 알려져 있다. 그 중에서도 매실의 중요한 성분 중에 하나인 루틴(rutin)은 혈관계 질환의 치료와 모세혈관 강화, 항염증 효과에 도움을 주며, 항산화 효능을 발휘한다고 보고되고 있고 항산화 효능을 이용한 미백효능에 대한 연구도 진행되었다.Plum tree (Prunus mume) belongs to the Rosaceae family, and its origin is in the southeastern part of China, and it is an endemic fruit tree of the East distributed in the warm regions of Korea, China and Japan. In addition, it has been used for edible or medicinal purposes since ancient times to the extent that it appeared in Nagwanjung’s “Three Kingdoms”. In various oriental medicine books, there are records of treatment of plums such as chronic cough, gastritis, chronic death, hematuria, vomiting, and hemorrhoids. Plums contain a lot of organic acids and minerals such as malic acid, citric acid, oxalic acid, succinic acid, and fumaric acid, and are known to have the effect of promoting appetite and increasing gastric juice secretion to help digestive activity and fatigue recovery. Among them, rutin, one of the important components of plum, helps treat vascular disease, strengthens capillaries, and has anti-inflammatory effects, and is reported to exhibit antioxidant effects, and studies on whitening efficacy using antioxidant effects are also underway. Became.
본 발명에서는 매실과 글루타티온(Glutathione)을 함유하는 효모 혼합물이 항산화 및 미백 효과를 가지는 것을 확인하였고 이를 활용하고자 한다.In the present invention, it was confirmed that a yeast mixture containing plum and glutathione has antioxidant and whitening effects, and it is intended to be utilized.
이를 위하여 항산화 실험과 멜라닌 생합성 실험 및 이취 제거 및 과립화를 위하여 첨가한 HPMC에 의한 상기 항산화 활성과 미백효과의 영향 정도를 측정하는 실험을 하였다.To this end, an experiment was performed to measure the degree of influence of the antioxidant activity and whitening effect by HPMC added for the antioxidant experiment, melanin biosynthesis experiment, off-flavor removal and granulation.
실험방법Experiment method
1) 재료 및 시약1) Materials and reagents
DPPH (2,2-diphenyl-1-picrylhydrazyl), ABTS (2,2-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diamonium salt), Iron (Ⅲ) chloride, Potassium ferricyanide, Trichloroacetic acid, Iron(Ⅱ) chloride, 2,2’-Bipyridyl, Copper (Ⅱ) chloride, Ammonium acetate, Pyrogallol, Quercetin, Folin & Ciocalteu’s phenol reagent, Gallic acid, Vanillin, Catechin, TPTZ (2,4,6-tripyridyl-S-triazine), Ferric Chloride는 Sigma-Aldrich사 (St. Louis, Mo, USA)에서 각각 구입하여 사용하였다. Glacial acetic acid 는 Alfa Aesar(Thermo Fisher Scientific)에서 구입하여 사용하였으며 Sodium acetate trihydrate는 JUNSEI 에서 구입하여 사용하였다.DPPH (2,2-diphenyl-1-picrylhydrazyl), ABTS (2,2-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diamonium salt), Iron (Ⅲ) chloride, Potassium ferricyanide, Trichloroacetic acid, Iron( Ⅱ) chloride, 2,2'-Bipyridyl, Copper (Ⅱ) chloride, Ammonium acetate, Pyrogallol, Quercetin, Folin & Ciocalteu's phenol reagent, Gallic acid, Vanillin, Catechin, TPTZ (2,4,6-tripyridyl-S-triazine ), Ferric Chloride was purchased and used from Sigma-Aldrich (St. Louis, Mo, USA), respectively. Glacial acetic acid was purchased and used from Alfa Aesar (Thermo Fisher Scientific), and sodium acetate trihydrate was purchased and used from JUNSEI.
세포 배양에 사용된 Dulbecco’s Modified Eagle’s Medium (DMEM), penicillin-streptomycin, phosphate buffered saline (PBS) 및 fetal bovine serum (FBS) 는 Hyclone 제품을 구입하였고 DMSO, L-Dopa 는 Sigma-Aldrich사 (St. Louis,Mo, USA) 에서 각각 구입하여 사용하였다. CCK-8 (Cell Counting Kit-8) 은 Dojindo(Molecular Technologies, Inc.) 에서 구입하여 사용하였다. 그 외 연구에 사용된 용매 및 시약은 일급 및 특급 시약을 구입하여 사용하였다.Dulbecco's Modified Eagle's Medium (DMEM), penicillin-streptomycin, phosphate buffered saline (PBS) and fetal bovine serum (FBS) used for cell culture were purchased from Hyclone, and DMSO and L-Dopa were purchased from Sigma-Aldrich (St. Louis). ,Mo, USA) respectively purchased and used. CCK-8 (Cell Counting Kit-8) was purchased and used from Dojindo (Molecular Technologies, Inc.). For other solvents and reagents used in the study, first-class and special-grade reagents were purchased and used.
2) Fe chelating ability2) Fe chelating ability
Fe chelating 측정은 Dinis et all.(1994) 의 방법을 변형하여 측정한다. 시료 120μl에 FeCl solution (30μl, 0.6mM), Bipyridyl solution (30μl, 5mM) 을 차례로 가하여 10분간 반응 후 562nm에서 흡광도를 측정하였다. Fe chelating measurement is measured by modifying the method of Dinis et all. (1994). FeCl solution (30μl, 0.6mM) and Bipyridyl solution (30μl, 5mM) were sequentially added to 120μl of the sample, reacted for 10 minutes, and absorbance was measured at 562nm.
3) Tyrosinase activity inhibition test3) Tyrosinase activity inhibition test
3차 증류수에 희석한 시료 40μl에 67mM Sodium phosphate buffer (pH6.8) 80μl를 가하여 완충시킨다. 만들어 놓은 buffer을 사용하여 10mM L-DOPA (3,4-dihydroxy-L-phenylalanine) 를 용해 시켜 40μl를 넣어준다. 마지막으로 125unit의 tyrosinase (from mushroom) 40μl를 가하여 37℃에서 10분간 반응 후 492nm에서 측정하였다. To 40 μl of the sample diluted in tertiary distilled water, 80 μl of 67 mM sodium phosphate buffer (pH6.8) was added to buffer. Using the prepared buffer, dissolve 10mM L-DOPA (3,4-dihydroxy-L-phenylalanine) and add 40μl. Finally, 40 μl of 125 units of tyrosinase (from mushroom) was added and reacted at 37° C. for 10 minutes, and then measured at 492 nm.
4) 세포배양4) Cell culture
실험에 사용한 세포는 Mouse melanoma melanocyte B16F0 세포를 ATCC에서 분양받아 사용하였다. B16F0 세포는 10% heat-inactivated fetal bovine serum (FBS), penicillin 및 2-mercaptoethanol이 함유된 Dulbecco’s Modified Eagle’s Medium(DMEM) 배지에서 5% CO2, 37℃조건에서 배양하여 실험에 사용하였다. As for the cells used in the experiment, Mouse melanoma melanocyte B16F0 cells were distributed from ATCC and used. B16F0 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) medium containing 10% heat-inactivated fetal bovine serum (FBS), penicillin and 2-mercaptoethanol at 5% CO 2 and 37°C, and used in the experiment.
5) 세포 생존율 측정5) Cell viability measurement
세포 생존율은 CCK-8 (Cell Counting Kit-8) 시약을 이용하여 측정하였다. 96-well plate에 B16F0 세포를 1 × 105 cells/well 농도로 접종한 후 각 well에 시료를 농도별로 투여하여 CO2 배양기에서 72시간 배양하였다. CCK-8 용액을 첨가하고 3시간 후 micro plate reader ((주)Bio-tech) 를 이용하여 450 nm에서 흡광도를 측정하여 대조그룹과 비교하였다. Cell viability was measured using CCK-8 (Cell Counting Kit-8) reagent. B16F0 cells were inoculated into a 96-well plate at a concentration of 1 × 10 5 cells/well, and then samples were administered to each well by concentration, followed by incubation in a CO 2 incubator for 72 hours. After 3 hours after adding the CCK-8 solution, the absorbance was measured at 450 nm using a micro plate reader (Bio-tech Co., Ltd.) and compared with the control group.
6) 세포내 tyrosinase 활성 저해 효과 측정6) Measurement of the inhibitory effect of intracellular tyrosinase activity
외부자극에 따른 B16F0세포 내 tyrosinase 의 활성에 실험시료가 영향을 미치는지를 알아보기 위해 외부자극제로 α-MSH (200 nM)을 사용하였으며 세포내 tyrosinase 활성 저해는 Matinez-Esparza의 방법을 변형시켜 측정하였다. 6-well plate에 1 × 106 cells/well로 세포를 분주하고 positive control로 α-MSH를 처리하여 자극하였다. 1시간 후 시료를 처리하였고, 72시간 배양한 후, 세포를 수집하여 1% (W/V) Triton X-100을 함유한 0.1 M sodium phosphate buffer (pH 6.5)를 1ml 가하여 용해하였다. 그 후 원심분리하여 얻은 상등액을 tyrosinase 활성과 단백질 정량에 이용하고, cell pellet은 멜라닌 정량에 사용하였다. 96-well plate에 시료 처리 후 얻은 상등액 100 μL를 분주하고 0.2 μg/ml 3,4-hydroxyphenylalamine (DOPA)가 첨가된 0.1 M sodium phosphate buffer (pH 6.5)를 100 μL씩 넣고 37℃에서 2시간 배양한 다음 490 nm에서 흡광도를 측정하였다.Α-MSH (200 nM) was used as an external stimulator to determine whether the test sample had an effect on the tyrosinase activity in B16F0 cells due to external stimulation, and the inhibition of intracellular tyrosinase activity was measured by modifying the method of Matinez-Esparza. . Cells were aliquoted into a 6-well plate at 1 × 10 6 cells/well and stimulated by treating α-MSH as a positive control. Samples were treated after 1 hour, and after 72 hours incubation, cells were collected and dissolved by adding 1 ml of 0.1 M sodium phosphate buffer (pH 6.5) containing 1% (W/V) Triton X-100. Then, the supernatant obtained by centrifugation was used for tyrosinase activity and protein quantification, and the cell pellet was used for melanin quantification. Dispense 100 μL of the supernatant obtained after sample treatment into a 96-well plate, add 100 μL of 0.1 M sodium phosphate buffer (pH 6.5) to which 0.2 μg/ml 3,4-hydroxyphenylalamine (DOPA) is added, and incubate at 37°C for 2 hours. Then, the absorbance was measured at 490 nm.
7) 멜라닌 정량7) Melanin quantification
Tyrosinase 활성을 측정하는 과정에서 얻은 pellet에 10% DMSO를 함유한 1N NaOH 용액 200 μL를 가하고 90℃에서 water bath에서 30분 방치하여 멜라닌을 완전히 용해시킨 후 475 nm에서 흡광도를 측정하였다. 멜라닌 양은 합성 멜라닌을 사용하여 작성된 표준 검량선에서 구하고, 실험그룹의 멜라닌 양은 대조그룹의 멜라닌 양에 대한 백분율로 계산하였다. 멜라닌 양은 각 well에서 측정한 단백질 농도를 기준으로 μg/mg protein으로 표기하였다.200 μL of a 1N NaOH solution containing 10% DMSO was added to the pellet obtained in the process of measuring the tyrosinase activity, and allowed to stand in a water bath at 90° C. for 30 minutes to completely dissolve melanin, and the absorbance was measured at 475 nm. The amount of melanin was obtained from a standard calibration curve prepared using synthetic melanin, and the amount of melanin in the experimental group was calculated as a percentage of the amount of melanin in the control group. The amount of melanin was expressed as μg/mg protein based on the protein concentration measured in each well.
8) 통계분석8) Statistical analysis
모든 결과는 3반복으로 실험하여 측정치를 평균값±표준편차로 나타내었으며 실험 결과의 통계적 유의성은 Student’s t-test로 하였으며 p 값이 0.05 미만일 때 통계적으로 유의성이 있다고 판단하였다. All the results were tested in three repetitions, and the measured values were expressed as the mean value ± standard deviation. The statistical significance of the experimental results was set to Student's t- test, and when the p value was less than 0.05, it was judged that there was statistical significance.
(p values *<0.05, **<0.01, ***<0.001 vs. control group, #<0.05, ##<0.01, ###<0.001 vs. α-MSH group $<0.05, $$<0.01, $$$<0.001 vs. (-)Glutathione group,)( p values * <0.05, ** <0.01, *** <0.001 vs. control group, # <0.05, ## <0.01, ### <0.001 vs. α-MSH group $ <0.05, $$ <0.01 , $$$ <0.001 vs. (-)Glutathione group,)
- 실험결과- Experiment result
1) Fe chelating ability1) Fe chelating ability
2가 철의 chelating 능력은 금속이온의 산화 반응을 유도하고 대조군과 실험군의 시료가 산화를 얼마나 저해 하는지를 확인하기 위한 실험이며, 그 결과 100배 희석농도에서 Glutathione 효모를 포함하지 않은 대조군(1.5%) 보다 Glutathione 효모를 포함한 실험군(1.5%)에서만 유의적인 저해효과를 나타내었다 (Fig. 4). The chelating ability of divalent iron is an experiment to induce an oxidation reaction of metal ions and to determine how much the samples of the control group and the experimental group inhibit oxidation. As a result, the control group that did not contain Glutathione yeast at a 100-fold dilution concentration (1.5%) More than that, only the experimental group (1.5%) containing Glutathione yeast showed a significant inhibitory effect (Fig. 4).
2) Tyrosinase inhibition rate2) Tyrosinase inhibition rate
세포내의 미백 활성을 확인하기 전 효소적 반응을 통한 이화학적 미백 활성 실험을 진행하였다. 체내의 미백관련 멜라닌 색소의 침착을 막기 위해서는 Tyrosinase의 활성을 낮춰야한다. 이러한 목적으로 Tyrosinase(from mushroom)을 이용하여 효소 활성 저해율을 측정하였다. 그 결과로 100배 희석액의 경우 Glutathione효모를 포함한 실험군(1.0%, 1.5%)에서 Glutathione 효모를 포함하지 않은 대조군에 비해 각각 1.0%에서는 16%, 1.5%에서는 12% 더 높은 저해율을 나타내었다 (Fig. 5).Before confirming the intracellular whitening activity, a physicochemical whitening activity experiment was conducted through an enzymatic reaction. In order to prevent the deposition of whitening-related melanin pigment in the body, it is necessary to lower the activity of Tyrosinase. For this purpose, the enzyme activity inhibition rate was measured using Tyrosinase (from mushroom). As a result, in the case of the 100-fold dilution, the experimental group (1.0%, 1.5%) containing Glutathione yeast showed a 16% higher inhibition rate than the control group not containing Glutathione yeast, respectively, 16% at 1.0% and 12% at 1.5% (Fig. 5).
3) B16F0세포의 생존율3) Survival rate of B16F0 cells
실험시료가 마우스 유래 악성 흑색종 세포인 B16F0 세포 생존율에 미치는 영향을 알아보기 위하여 X50배와 X100배의 희석배율을 선정하여 실험에 사용 하였으며 Figure 6의 결과, 세포 독성이 없음을 확인하였다 (Fig. 6). In order to investigate the effect of the experimental sample on the survival rate of mouse-derived malignant melanoma cells, B16F0 cells, X50 times and X100 times dilution ratios were selected and used in the experiment. As a result of Figure 6, it was confirmed that there was no cytotoxicity (Fig. 6).
4) 세포 내 tyrosinase 활성 저해 효과4) Inhibitory effect of intracellular tyrosinase activity
타이로시네이즈 (Tyrosinase) 는 멜라닌 합성 과정에서 속도결정단계인 초기 반응에 관여하는 가장 중요한 효소이다. 또한 멜라닌 합성의 주요한 단계를 나타내는 효소로 타이로신 (tyrosin) 을 DOPA로 전환하는 tyrosine hydroxylase 활성과 DOPA를 DOPAquinone으로 산화하는 DOPA oxidase 활성을 가지고 있다. 또한 매실추출물에서 tyrosinase 의 활성을 억제한다는 연구 결과가 보고 되어 있고 이에 대조군에 비해 글루타치온 효모를 함유한 실험시료의 경우 tyrosinase 활성을 얼마나 더 억제하는지 확인하고자 하였다. 또한 외부자극에 따른 B16FO세포 내tyrosinase의 활성 및 과생성멜라닌에 대해 실험시료의 영향을 확인하기 위해 외부자극제로 α-MSH (200 nM) 을 사용하였다. 그 결과 두 시료 모두 B16f0세포의 tyrosinase 의 활성에 크게 영향을 미치지 않는 것을 확인하였다 (Fig. 7). Tyrosinase is the most important enzyme involved in the initial reaction, which is the rate-determining step in the melanin synthesis process. In addition, it has tyrosine hydroxylase activity that converts tyrosine to DOPA as an enzyme representing a major step in melanin synthesis, and DOPA oxidase activity that oxidizes DOPA to DOPAquinone. In addition, studies have reported that plum extract inhibits the activity of tyrosinase, and this was to confirm how much more inhibited tyrosinase activity in the experimental sample containing glutathione yeast compared to the control group. In addition, α-MSH (200 nM) was used as an external stimulator to confirm the effect of experimental samples on tyrosinase activity and overproduced melanin in B16FO cells according to external stimulation. As a result, it was confirmed that both samples did not significantly affect the tyrosinase activity of B16f0 cells (Fig. 7).
5) 멜라닌 생합성 저해 효과5) Melanin biosynthesis inhibitory effect
B16F0 악성 흑색종 멜라노마 세포를 이용한 멜라닌 생합성 저해 효과는 Matinez-Esparza 의 방법을 변형시켜 측정하였다. B16F0 악성 흑색종 멜라노마 세포에 실험시료를 희석배율 별로 처리하고 72시간 배양한 다음 멜라닌 생성량을 측정하였다. 그 결과 대조군에 비해 글루타치온 효모를 함유한 실험시료의 경우 X50배로 희석한 그룹에서는 통계적으로 유의하게 멜라닌 생합성을 저해하는 효과를 나타내었지만 positive control그룹에 비교해서 통계적으로 유의하게 멜라닌 생합성을 저해하지 않았으며, X100 배로 희석하여 처리한 그룹에서는 크게 차이를 나타내지 않는 것을 확인하였다 (Fig. 8).The inhibitory effect of melanin biosynthesis using B16F0 malignant melanoma melanoma cells was measured by modifying the method of Matinez-Esparza. B16F0 malignant melanoma melanoma cells were treated with different dilution ratios and cultured for 72 hours, and then the amount of melanin production was measured. As a result, compared to the control group, the experimental sample containing glutathione yeast showed a statistically significant inhibitory effect on melanin biosynthesis in the X50-fold dilution group, but did not significantly inhibit melanin biosynthesis compared to the positive control group. , It was confirmed that there was no significant difference in the group treated by dilution by X100 times (Fig. 8).
6) 항산화 활성 측정6) Measurement of antioxidant activity
Glutathione 효모를 1.5% 함유한 대조군과 과립화를 위해 HPMC를 첨가한 실험군, 그리고 과립화한 후 H2O로 용해한 실험군의 항산화 활성을 비교하였다. 그 결과 대조군에 비해 HPMC를 첨가한 실험군, 과립화한 후 H2O로 용해한 실험군에서 유의한 항산화 활성의 차이는 없었다. 따라서 과립화로 인한 항산화 활성은 감소하지 않는 것을 확인하였다 (Fig. 9-12).The antioxidant activity of the control group containing 1.5% glutathione yeast, the experimental group to which HPMC was added for granulation, and the experimental group dissolved in H 2 O after granulation were compared. As a result, there was no significant difference in antioxidant activity in the experimental group to which HPMC was added and the experimental group to which H 2 O was dissolved after granulation compared to the control group. Therefore, it was confirmed that the antioxidant activity did not decrease due to granulation (Fig. 9-12).
7) Tyrosinase inhibition rate7) Tyrosinase inhibition rate
Glutathione 효모를 1.5% 함유한 대조군과 과립화를 위해 HPMC를 첨가한 실험군, 그리고 과립화한 후 H2O로 용해한 실험군의 Tyrosinase (from mushroom) 을 이용하여 효소 활성 저해율을 측정하였다. 그 결과 100배 희석한 그룹에서는 대조군에 비해 HPMC를 첨가한 실험군, 과립화 한 후 H2O로 용해한 실험군에서 유의한 항산화 활성의 차이는 없었다. 따라서 과립화로 인한 항산화 활성은 감소하지 않는 것을 확인하였다.The inhibition rate of enzyme activity was measured using Tyrosinase (from mushroom) of the control group containing 1.5% glutathione yeast, the experimental group to which HPMC was added for granulation, and the experimental group dissolved in H 2 O after granulation. As a result, in the 100-fold diluted group, there was no significant difference in antioxidant activity in the experimental group to which HPMC was added and the experimental group to which H 2 O was dissolved after granulation compared to the control group. Therefore, it was confirmed that the antioxidant activity did not decrease due to granulation.
본 발명의 항산화 및 미백 조성물Antioxidant and whitening composition of the present invention
본 발명은 매실과 글루타치온(Glutathione) 효모의 혼합물을 과립화하며 HPMC를 첨가한다.In the present invention, a mixture of plum and glutathione yeast is granulated and HPMC is added.
상기 HPMC는 propylene glycol ether of methylcellulose 의 약자로, 화학적 구조는 셀룰로오스 주사슬로 구성되어 있고, 여기서 치환체 R은 H, -CH3이거나 -CH2CH(CH3)OH 이다.The HPMC stands for propylene glycol ether of methylcellulose, and its chemical structure is composed of a cellulose main chain, where the substituent R is H, -CH3 or -CH2CH(CH3)OH.
셀룰로오스는 하이드록시 그룹의 강한 수소결합으로 인해 결정을 형성하여 물에 잘 녹지 않지만 HPMC는 비이온성을 나타내어 물에 대한 용해도가 높고 낮은 온도에서도 잘 용해되어, 점성이 있는 콜로이드 용액을 형성한다. 클로로포름, 에탄올, 에테르 등과 같은 유기 용매에는 거의 용해되지 않으나 에탄올과 디클로로메탄, 메탄올과 디클로로메탄, 물과 알콜의 혼합액에는 용해된다. 그리고 일반적으로 무미, 무취의 백색 분말로 자극성, 독성이 없으며 인체에 무해하다.Cellulose forms crystals due to strong hydrogen bonds of hydroxy groups and is not well soluble in water, but HPMC has high solubility in water and is well soluble at low temperatures, forming a viscous colloidal solution. It is hardly soluble in organic solvents such as chloroform, ethanol, and ether, but it is soluble in a mixture of ethanol and dichloromethane, methanol and dichloromethane, and water and alcohol. In general, it is a tasteless, odorless white powder that is not irritating or toxic, and is harmless to the human body.
HPMC의 물리화학적 특성은 i) -OCH3 그룹의 비, ii) -OCH2CH(CH3)OH 그룹의 비, iii) 분자량과 관계가 있다. 미국약전(USP)에서는 HPMC의 종류를 표 1과 같이 -OCH3, -OCH2CH(CH3)OH의 비율에 따라서 HPMC1828, HPMC2208(K), HPMC2906(F), HPMC2910(E)으로 정의하고 있다. 앞의 두 숫자는 -OCH3 그룹의 비율이고, 뒤의 두 숫자는 -OCH2CH(CH3)OH 그룹의 비율이다. 모든 등급의 HPMC가 다양한 제제에서 널리 이용되는데, 특히 약물방출제어에 사용되는 것은 주로 상대적으로 점도가 높은 2208과 2910등급이다.The physicochemical properties of HPMC are related to i) the ratio of -OCH3 groups, ii) the ratio of -OCH2CH(CH3)OH groups, and iii) the molecular weight. The United States Pharmacopoeia (USP) defines the types of HPMC as HPMC1828, HPMC2208(K), HPMC2906(F), and HPMC2910(E) according to the ratio of -OCH3, -OCH2CH(CH3)OH as shown in Table 1. The first two numbers are the ratio of the -OCH3 group, and the second two numbers are the ratio of the -OCH2CH(CH3)OH group. All grades of HPMC are widely used in various formulations, especially those used for drug release control are mainly grades 2208 and 2910, which have relatively high viscosity.
미국약전(USP)에서는 HPMC의 점도측정법을 20 ℃에서 2%용액으로 만들어 측정한다고 제시하고 있다. 이때 HPMC의 점도는 측정온도에 따라 크게 변하게 되는데 그 이유는 HPMC가 특정 온도에서 젤로 변화하는 성질을 가지고 있기 때문이다. 온도에 따른 졸-젤-졸로의 상전이 현상은 분자내의 소수성 작용기들 간의 상호작용에 의해 중합체가 형성되기 때문이다. 또 다른 분류 방법으로는 HPMC의 등급에 따라 P: premium, LV: low viscosity, CR: controlled release, G: granular, S: surface treated, FG: food grade 등으로 나눠지기도 한다.The US Pharmacopoeia (USP) suggests that HPMC's viscosity measurement method is made into a 2% solution at 20°C. At this time, the viscosity of HPMC varies greatly depending on the measurement temperature, because HPMC has a property of changing to a gel at a specific temperature. The sol-gel-zolo phase transition phenomenon according to temperature is because a polymer is formed by the interaction between hydrophobic functional groups in the molecule. Another classification method is classified into P: premium, LV: low viscosity, CR: controlled release, G: granular, S: surface treated, and FG: food grade, depending on the grade of HPMC.
본 발명에서 HPMC는 매실과 글루타치온 효모를 코팅하며 결합하여 과립화하는 결합제로 사용하였다. 이러한 구성에 의하여 글루타치온 효모에서 발생하는 이취를 섭취 시 복용자가 느낄 수 없도록 하였다. In the present invention, HPMC was used as a binder to coat, combine, and granulate plum and glutathione yeast. This configuration prevented the user from feeling the off-flavor generated from glutathione yeast when ingested.
본 발명은 사용자의 섭취 편의와 기능을 향상하기 위하여 매실농축액, 결정과당, 자일리톨, 미네랄, 비타민, 글루타치온 효모(글루타치온 50% 함유), 포도당을 하기 샘플1 내지 3의 비율로 혼합하여 사용하였다.In the present invention, plum concentrate, crystal fructose, xylitol, minerals, vitamins, glutathione yeast (containing 50% glutathione), and glucose were mixed and used in the following samples 1 to 3 in order to improve the convenience and function of the user's intake.
본 발명의 항산화 및 미백 조성물은 매실 5 중량%, 자일리톨 50 중량%, 결정과당 29.5 중량%, 비타민C 7%, 미네랄 3 중량%, 50 중량%의 글루타치온을 함유하는 글루타치온 효모 0.5 중량% 인 것을 특징으로 하는 항산화 및 미백 조성물을 제공한다.The antioxidant and whitening composition of the present invention is 0.5% by weight of glutathione yeast containing 5% by weight of plum, 50% by weight of xylitol, 29.5% by weight of crystalline fructose, 7% of vitamin C, 3% by weight of minerals, and 0.5% by weight of glutathione. It provides an antioxidant and whitening composition.
또 다른 실시예로, 본 발명의 항산화 및 미백 조성물은 매실 5 중량%, 자일리톨 50 중량%, 결정과당 29 중량%, 비타민C 7%, 미네랄 3 중량%, 50 중량%의 글루타치온을 함유하는 글루타치온 효모 1 중량% 인 것을 특징으로 하는 항산화 및 미백 조성물을 제공한다.In another embodiment, the antioxidant and whitening composition of the present invention is a glutathione yeast containing 5% by weight of plum, 50% by weight of xylitol, 29% by weight of crystalline fructose, 7% of vitamin C, 3% by weight of minerals, and 50% by weight of glutathione. It provides an antioxidant and whitening composition, characterized in that 1% by weight.
또 다른 실시예로, 본 발명의 항산화 및 미백 조성물은 매실 5 중량%, 자일리톨 50 중량%, 결정과당 28.5 중량%, 비타민C 7%, 미네랄 3 중량%, 50 중량%의 글루타치온을 함유하는 글루타치온 효모 1.5 중량% 인 것을 특징으로 하는 항산화 및 미백 조성물을 제공한다.In another embodiment, the antioxidant and whitening composition of the present invention is a glutathione yeast containing 5% by weight of plum, 50% by weight of xylitol, 28.5% by weight of fructose, 7% of vitamin C, 3% by weight of minerals, and 50% by weight of glutathione. It provides an antioxidant and whitening composition, characterized in that 1.5% by weight.
상기 배합비로 배합된 조성물을 하기의 방법으로 과립화하였다.The composition blended in the above blending ratio was granulated by the following method.
매실농축액 (10 Bix)를 기반으로 자일리톨, 결정과당, 비타민C, 미네랄 글루타치온 효모 분말(글루타치온 50% 함유)를 배합하여 액상 재료를 준비하는 혼합조성물 제조단계(S1); 및 A mixed composition preparation step (S1) of preparing a liquid material by mixing xylitol, crystal fructose, vitamin C, and mineral glutathione yeast powder (containing 50% glutathione) based on plum concentrate (10 Bix); And
유동층 과립기의 공정온도를 50℃로 설정하여 슈가 시드(sugger seed)을 과립화를 위한 핵으로 사용하여 과립화하는 과립화공정(S2); A granulation step (S2) of granulating using a sugar seed as a nucleus for granulation by setting the process temperature of the fluid bed granulator to 50°C;
상기 과립화공정에서 과립화된 조성물 과립을 HMPC로 코팅하여 상기 과립이 수분을 흡수하여 뭉치는 것을 방지하는 HMPC코팅공정(S3);을 포함하는 것을 특징으로 하는 매실과 글루타치온 효모를 구비한 항산화 및 미백 조성물을 제공한다. Antioxidant comprising plum and glutathione yeast, comprising: an HMPC coating process (S3) in which the granules of the composition granulated in the granulation process are coated with HMPC to absorb moisture and prevent agglomeration of the granules. Provides a whitening composition.
상기 슈가 시드의 직경은 0.3mm의 것을 사용하는 것을 특징으로 하는 매실과 글루타치온 효모를 구비한 항산화 및 미백 조성물을 제공한다.It provides an antioxidant and whitening composition comprising plum and glutathione yeast, characterized in that the sugar seed has a diameter of 0.3mm.
상기 공정온도는 60℃ 이하인 것을 특징으로 한다. 60℃가 되면 상기 혼합조성물이 모두 용해되어 과립화가 불가능하기 때문이다.The process temperature is characterized in that less than 60 ℃. This is because when the temperature reaches 60° C., all of the mixed composition is dissolved and granulation is impossible.
삭제delete
Claims (3)
유동층 과립기의 공정온도를 50℃로 설정하여 슈가 시드(sugger seed)을 과립화를 위한 핵으로 사용하여 과립화하는 과립화공정(S2);
상기 과립화공정에서 과립화된 조성물 과립을 HMPC로 코팅하여 상기 과립이 수분을 흡수하여 뭉치는 것을 방지하는 HMPC코팅공정(S3);을 포함하는 것을 특징으로 하는 매실과 글루타치온 효모를 구비한 항산화 및 미백 조성물.A mixed composition prepared by mixing 5% by weight of plum, 50% by weight of xylitol, 29.5% by weight of crystalline fructose, 7% of vitamin C, 3% by weight of minerals, and 0.5% by weight of glutathione yeast containing 50% by weight of glutathione Step (S1); And
A granulation step (S2) of granulating using a sugar seed as a nucleus for granulation by setting the process temperature of the fluid bed granulator to 50°C;
Antioxidant comprising plum and glutathione yeast, comprising: an HMPC coating process (S3) in which the granules of the composition granulated in the granulation process are coated with HMPC to absorb moisture and prevent agglomeration of the granules. Whitening composition.
유동층 과립기의 공정온도를 50℃로 설정하여 슈가 시드(sugger seed)을 과립화를 위한 핵으로 사용하여 과립화하는 과립화공정(S2);
상기 과립화공정에서 과립화된 조성물 과립을 HMPC로 코팅하여 상기 과립이 수분을 흡수하여 뭉치는 것을 방지하는 HMPC코팅공정(S3);을 포함하는 것을 특징으로 하는 매실과 글루타치온 효모를 구비한 항산화 및 미백 조성물.A mixed composition prepared by mixing 5% by weight of plum, 50% by weight of xylitol, 29% by weight of crystalline fructose, 7% of vitamin C, 3% by weight of minerals, and 1% by weight of glutathione yeast containing 50% by weight of glutathione Step (S1); And
A granulation step (S2) of granulating using a sugar seed as a nucleus for granulation by setting the process temperature of the fluid bed granulator to 50°C;
Antioxidant comprising plum and glutathione yeast, comprising: an HMPC coating process (S3) in which the granules of the composition granulated in the granulation process are coated with HMPC to absorb moisture and prevent agglomeration of the granules. Whitening composition.
유동층 과립기의 공정온도를 50℃로 설정하여 슈가 시드(sugger seed)을 과립화를 위한 핵으로 사용하여 과립화하는 과립화공정(S2);
상기 과립화공정에서 과립화된 조성물 과립을 HMPC로 코팅하여 상기 과립이 수분을 흡수하여 뭉치는 것을 방지하는 HMPC코팅공정(S3);을 포함하는 것을 특징으로 하는 매실과 글루타치온 효모를 구비한 항산화 및 미백 조성물.A mixed composition prepared by mixing 5% by weight of plum, 50% by weight of xylitol, 28.5% by weight of crystalline fructose, 7% of vitamin C, 3% by weight of minerals, and 1.5% by weight of glutathione yeast containing 50% by weight of glutathione Step (S1); And
A granulation step (S2) of granulating using a sugar seed as a nucleus for granulation by setting the process temperature of the fluid bed granulator to 50°C;
Antioxidant comprising plum and glutathione yeast, comprising: an HMPC coating process (S3) in which the granules of the composition granulated in the granulation process are coated with HMPC to absorb moisture and prevent agglomeration of the granules. Whitening composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190056913A KR102247944B1 (en) | 2019-05-15 | 2019-05-15 | Antioxidant and whitening composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190056913A KR102247944B1 (en) | 2019-05-15 | 2019-05-15 | Antioxidant and whitening composition |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20200133047A KR20200133047A (en) | 2020-11-26 |
KR102247944B1 true KR102247944B1 (en) | 2021-05-06 |
Family
ID=73679277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190056913A KR102247944B1 (en) | 2019-05-15 | 2019-05-15 | Antioxidant and whitening composition |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102247944B1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009001786A1 (en) * | 2007-06-22 | 2008-12-31 | Kaneka Corporation | Composition containing physiologically active substance |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040005407A (en) * | 2002-07-10 | 2004-01-16 | 이명석 | Anti-aging composition |
KR101704874B1 (en) * | 2014-08-18 | 2017-02-09 | 유민정 | Cosmetic Compositions with Whitening and Anti-oxidative Effect Comprising of Phragmitis Rhizoma, Salicomia herbacea L. and Prunus mume |
KR101768626B1 (en) | 2014-12-05 | 2017-09-28 | 재단법인 경기도경제과학진흥원 | Skin whitening composition comprising an extract obtained from carthamus tinctorius l. |
-
2019
- 2019-05-15 KR KR1020190056913A patent/KR102247944B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009001786A1 (en) * | 2007-06-22 | 2008-12-31 | Kaneka Corporation | Composition containing physiologically active substance |
Also Published As
Publication number | Publication date |
---|---|
KR20200133047A (en) | 2020-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090017141A1 (en) | Topical composition for the treatment of hyperpigmented skin | |
WO2006075865A1 (en) | Skin-condition improving composition comprising vaccinium uliginosum extract and method for preparation thereof | |
Yang et al. | Dietary enzyme-treated Hibiscus syriacus L. protects skin against chronic UVB-induced photoaging via enhancement of skin hydration and collagen synthesis | |
Hamid et al. | Mangosteen leaf extract increases melanogenesis in B16F1 melanoma cells by stimulating tyrosinase activity in vitro and by up-regulating tyrosinase gene expression | |
EP1737538B1 (en) | Topical depigmenting formulations comprising an extract of bellis perennis | |
EP2394635A1 (en) | Skin-whitening agent, anti-aging agent, and anti-oxidant agent | |
JP2000069938A (en) | Skin whitening agent for oral intake and its use | |
KR20080049332A (en) | Skin-whitening extract from oviductus ranae | |
KR100710657B1 (en) | Whitening cosmetic composition containing dihydroquercetin | |
KR20100121352A (en) | A composition comprising complex crude drug extract for anti-aging and improvement of skin | |
KR101787289B1 (en) | Compositions having inhibitory effect on induction of grey hair and positive effect on induction of black hair | |
KR20170048904A (en) | Cosmetic compositions for skin whitening containing costunolide from natural extracts | |
KR102247944B1 (en) | Antioxidant and whitening composition | |
KR20210090790A (en) | Melanin production inhibitory skin whitening cosmetic composition | |
US10980736B2 (en) | Coconut shell extracts, compositions containing same and uses | |
KR102247947B1 (en) | Antioxidant and whitening composition granulation method and composition prepared thereby | |
KR101456059B1 (en) | The cosmetic composition effective in whitening and anti-aging mainly comprised of roasted licorice extract | |
KR101128990B1 (en) | Composition for skin whitening consist of plant exract and cosmetic compostion comprising the plant extract compostion | |
KR100864203B1 (en) | Malus micromalus extracts having whitening activity | |
KR102030419B1 (en) | A composition comprising graviola having inhibitory effect on induction of grey hair and positive effect on induction of black hair | |
KR20030012562A (en) | Whitening composition containing rhodiola sachalinensis a. bor extraction | |
KR20160132151A (en) | Skin agent composition | |
KR20090111679A (en) | Whitening cosmetic composition including the extract of Astragali Radix | |
KR101777368B1 (en) | Composition for skin-whitener containing extract of china rose | |
KR20190063600A (en) | Composition for skin whitening comprising extract of stichopus japonicas red |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |